July 2 (Reuters) - Eli Lilly and Co Lly.n:
Lilly's Kisunla™ (Donanemab-Azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly: Price of Each Vial of Kisunla Is $695.65
Eli Lilly: Coverage & Reimbursement for Kisunla Now Available for Eligible Patients on Medicare
Eli Lilly: Kisunla 6 Months Length of Treatment With 6 30-Minute Infusions to Cost $12,522
Eli Lilly - Kisunla 12 Months Length of Treatment With 13 30-Minute Infusions to Cost $32,000
Eli Lilly: Intends to Donate Kisunla to Lilly Cares Foundation
Source Text for Eikon: Id:Npn5Yfd56a
Further Company Coverage: Lly.n